Lupin launches Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States. Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent® Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals, Inc.

Ipratropium Bromide Nasal Solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. Ipratropium Bromide Nasal Solution (Nasal Spray) 0.06% is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older.

Ipratropium Bromide Nasal Solution (RLD Atrovent®) had estimated annual sales of USD 63 million in the U.S. (IQVIA MAT May 2025).

Shares of Lupin Limited was last trading in BSE at Rs. 1955.60 as compared to the previous close of Rs. 1967.60. The total number of shares traded during the day was 13290 in over 1333 trades.

The stock hit an intraday high of Rs. 1983.65 and intraday low of 1939.50. The net turnover during the day was Rs. 25899728.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals IpratropiumBromide NasalSpray